The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Ivanova S.A.

Nauchno-issledovatel'skiĭ institut psikhicheskogo zdorov'ia Sibirskogo otdeleniia Rossiĭskoĭ akademii meditsinskikh nauk, Tomsk

Alifirova V.M.

Sibirskiĭ gosudarstvennyĭ meditsinskiĭ universitet, Tomsk, Russia

Zhukova I.A.Жукова Ирина Александровна

Siberian State Medical University, Tomsk

Boyko A.S.

Mental Health Research Institute, Tomsk

Fedorenko O.Iu.

Nauchno-issledovatel'skiĭ institut psikhicheskogo zdorov'ia Sibirskogo otdeleniia Rossiĭskoĭ akademii meditsinskikh nauk, Tomsk;
Natsional'nyĭ issledovatel'skiĭ Tomskiĭ politekhnicheskiĭ universitet, Tomsk

Zhukova N.G.

Siberian State Medical University, Tomsk, Russia

Bokhan N.A.

Nauchno-issledovatel'skiĭ institut psikhicheskogo zdorov'ia Tomskogo nauchnogo tsentra Sibirskogo otdeleniia RAMN

The association of the DRD3 gene with Parkinson’s disease

Authors:

Ivanova S.A., Alifirova V.M., Zhukova I.A.Жукова Ирина Александровна, Boyko A.S., Fedorenko O.Iu., Zhukova N.G., Bokhan N.A.

More about the authors

Read: 1507 times


To cite this article:

Ivanova SA, Alifirova VM, Zhukova IAЖукова Ирина Александровна, Boyko AS, Fedorenko OIu, Zhukova NG, Bokhan NA. The association of the DRD3 gene with Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2016;116(5):71‑74. (In Russ.)
https://doi.org/10.17116/jnevro20161165171-74

Recommended articles:
Neuroinflammatory and neurodegenerative aspe­cts of Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):102-111
Schi­zophrenic spectrum diso­rders and Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):136-141
Art and creativity in Parkinson’s disease: the mysterious effe­cts of dopa­mine. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):13-20
Correlation of motor symptoms and cardiovascular dysfunction in Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):59-67
Sleep diso­rders in patients with Lewy body deme­ntia and Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):81-87
Effect of uric acid on the progression of Parkinson’s disease: Myth or reality?. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7):7-14

References:

  1. Zhukova IA, Zhukova NG, Alifirova VM, Gashilova FF. Kognitivnye rasstrojstva i kachestvo zhizni pacientov s bolezn'ju Parkinsona. Bjulleten' sibirskoj mediciny. 2008;7:5(1):145-149. (In Russ.).
  2. Illarioshkin SN, Levin OS. Bolezn' Parkinsona i rasstrojstva dvizhenij. M.: ZAO «RKI Sovero press»; 2014. (In Russ.).
  3. Jahno NN, Shtul'man DR. Bolezni nervnoj sistemy. M.: Medicina; 2001. (In Russ.).
  4. Alonso-Navarro H, Javier Jimenez-Jimenez F, Garcia-Martin E, AG Agundez J. Genomic and pharmacogenomic biomarkers of Parkinson’s disease. Current drug metabolism. 2014;15(2):129-181.  doi: 10.2174/138920021502140327175404.
  5. Subramaniam SR, Chesselet M-F. Mitochondrial dysfunction and oxidative stress in Parkinson’s disease. Progress in neurobiology. 2013;106:17-32.  doi: 10.1016/j.pneurobio.2013.04.004.
  6. Shadrina MI, Slominskij PA. Znachenie mitohondrial'noj disfunkcii i okislitel'nyh povrezhdenij v molekuljarnoj patologii bolezni Parkinsona. Molekuljarnaja biologija. 2008;42:5:809-819. (In Russ.).
  7. Bekris LM, Mata IF, Zabetian CP. The genetics of Parkinson’s disease. J. of geriatric psychiatry and neurology. 2010;23(4):228-242.  doi: 10.1177/0891988710383572.
  8. Illarioshkin SN, Ivanova-Smolenskaja IA, Markova ED, Shadrina MI, Kljushnikov SA, Zagorovskaja TB, Miklina NI, Slominskij PA, Limborskaja SA. Molekuljarno-geneticheskij analiz nasledstvennyh nejrodegenerativnyh zabolevanij. Genetika. 2004;40:6:816-826. (In Russ.).
  9. Hauser DN, Hastings TG. Mitochondrial dysfunction and oxidative stress in Parkinson’s disease and monogenic parkinsonism. Neurobiology of disease. 2013;51:35-42.  doi: 10.1016/j.nbd.2012.10.011.
  10. Xu Z, Taylor JA. SNPinfo: integrating GWAS and candidate gene information into functional SNP selection for genetic association studies. Nucleic acids research. 2009;37(suppl 2):600-605.  doi: 10.1093/nar/gkp290.
  11. Dai D, Wang Y, Wang L et al. Polymorphisms of DRD2 and DRD3 genes and Parkinson’s disease: A meta-analysis. Biomedical reports. 2014;2(2):275-281.  doi: 10.3892/br.2014.220.
  12. Thompson J, Thomas N, Singleton A et al. D2 dopamine receptor gene (DRD2) Taql A polymorphism: reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele. Pharmacogenetics and Genomics. 1997;7(6):45-54. http://journals.lww.com/jpharmacogenetics/Fulltext/1997/12000/D2_dopamine_receptor_gene__DRD2__Taql_A.6.aspx. doi: 10.1097/00008571-199712000-00006.
  13. Hadithy AAl, Ivanova S, Pechlivanoglou P et al. Tardive dyskinesia and DRD3, HTR2A and HTR2C gene polymorphisms in Russian psychiatric inpatients from Siberia. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2009;33(3):475-481.  doi: 10.1016/j.pnpbp.2009.01.010.
  14. Loonen AJ, Ivanova SA. New insights into the mechanism of drug-induced dyskinesia. CNS spectrums. 2013;18(01):15-20.  doi: 10.1017/S1092852912000752.
  15. McGuire V, Van Den Eeden S, Tanner C et al. Association of DRD2 and DRD3 polymorphisms with Parkinson’s disease in a multiethnic consortium. J of the neurological sciences. 2011;307(1):22-29.  doi: 10.1016/j.jns.2011.05.031.
  16. Wang J, Liu Z-L, Chen B. Polymorphisms of dopamine D3-receptor gene and parkinson disease. Chinese Journal of New Drugs and Clinical Remedies. 2000;19(2):108-110.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.